Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1985 Feb;40(2):113–120. doi: 10.1136/thx.40.2.113

Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978-9: chemotherapy and hospital admission. Medical Research Council Tuberculosis and Chest Diseases Unit.

PMCID: PMC460000  PMID: 3975862

Abstract

The treatment of adult patients, both white and of Indian, Pakistani, or Bangladeshi ethnic origin, with previously untreated pulmonary tuberculosis who were notified in England and Wales from 1 October 1978 to 31 March 1979 has been surveyed. Chemotherapy was completed as planned by the physician in charge in 820 (65%) of the 1253 patients. Eleven per cent of patients died before chemotherapy could be completed, 8% defaulted, and 6% had chemotherapy modified because of drug toxicity, and for 8% there were miscellaneous reasons for failure to complete chemotherapy. Of the 1003 patients who completed chemotherapy, 804 (80%) were prescribed isoniazid and rifampicin throughout, 667 (67%) receiving ethambutol in addition, either in the initial phase (550) or throughout chemotherapy (117). A further 129 (13%) had a regimen based on isoniazid and ethambutol throughout, and the remaining 70 had miscellaneous combinations of drugs. For the 544 patients who received a two phase regimen of isoniazid and rifampicin throughout with one or two additional drugs initially and who completed chemotherapy as planned, the median duration of chemotherapy was 10.8 months, 122 (22%) patients being treated for more than 12 months. For all 1001 patients who completed chemotherapy (whether or not as planned) and for whom the duration was known, the median duration was 11.8 months and 311 (31%) had more than 12 months' treatment. The great majority (79%) of the patients were admitted to hospital initially, the commonest reason being for investigation and diagnosis.

Full text

PDF
113

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boman G., Calissendorff B. A case of irreversible bilateral optic damage after ethambutol therapy. Scand J Respir Dis. 1974;55(3):176–180. [PubMed] [Google Scholar]
  2. Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis-I. Br Med J (Clin Res Ed) 1983 Jul 2;287(6384):33–35. doi: 10.1136/bmj.287.6384.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Humphries M. J., Byfield S. P., Darbyshire J. H., Davies P. D., Nunn A. J., Citron K. M., Fox W. Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales. Br J Dis Chest. 1984 Apr;78(2):149–158. [PubMed] [Google Scholar]
  4. Monie R. D., Hunter A. M., Rocchiccioli K., White J., Campbell I. A., Kilpatrick G. S. Survey of pulmonary tuberculosis in south and west Wales (1976-8). Br Med J (Clin Res Ed) 1982 Feb 20;284(6315):571–573. doi: 10.1136/bmj.284.6315.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Pretet S., Lotte A., Marsac J., Choudat D. Coût théorique du traitement médical d'un cas de tuberculose en France en 1982. Rev Fr Mal Respir. 1983;11(5):677–685. [PubMed] [Google Scholar]
  6. Scott R., Gaskell P. G., Morrell D. C. Patients who reside in common lodging-houses. Br Med J. 1966 Dec 24;2(5529):1561–1564. doi: 10.1136/bmj.2.5529.1561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Simon G. Radiology in epidemiological studies and some therapeutic trials. Br Med J. 1966 Aug 27;2(5512):491–494. doi: 10.1136/bmj.2.5512.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tripathy S. P. Essai clinique contrôlé d'un régime de trois mois et de deux régimes de cinq mois dans le traitement de la tuberculose pulmonaire. Deuxième étude de traitement court poursuivie á Madras. Bull Int Union Tuberc. 1983 Jun;58(2):97–101. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES